Compare ARK Autonomous Technology & Robotics ETF (ARKQ) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ARK Autonomous Technology & Robotics ETF vs Viatris Inc — how do they compare? ARK Autonomous Technology & Robotics ETF trades at $122.9, while Viatris Inc trades at $16.27 (market cap $18.94B). The key difference: Viatris Inc pays a 2.95% dividend while ARK Autonomous Technology & Robotics ETF pays none, and Viatris Inc is trading nearer its 52-week high, ARK Autonomous Technology & Robotics ETF nearer its low. Which is the better fit depends on your goals.
| ARKQ | VTRS | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $143.82 | $17.39 |
52-Week Low | $91.86 | $8.74 |
Market Cap | — | $18.94B |
Enterprise Value | — | $31.15B |
Dividend Yield | — | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKQ trades at $123.99, down 0.57% with a bearish technical signal from moving averages. The ETF focuses on autonomous technology and robotics, benefiting from AI momentum with 57% gains since Q1 2026. Support levels cluster around $122-124 while resistance sits at $126-128. Recent news highlights China's EV targets and humanoid robotics growth projections reaching $200 billion by 2035.
The ETF shows strong momentum in AI and robotics themes but carries premium valuations with a 36x P/E ratio. Key risks include sector concentration and dependency on technological adoption rates. Institutional interest remains strong with $2.7 billion in assets, though technical indicators suggest near-term consolidation pressure.
Viatris (VTRS) trades at $16.27, down 0.43% on the day, with a bullish technical signal supported by moving averages. The stock has beaten EPS estimates for the last three quarters, though it reported a net loss of $3.51B in 2025. Revenue has declined from $16.3B in 2022 to $14.3B in 2025. Positive news includes FDA acceptance of a new drug application for fast-acting meloxicam and a Phase 3 study success for VR-205, targeting a Japanese NDA by end of 2026.
The outlook is mixed: analyst consensus is a $20 price target with a 'Hold' bias, but high debt and negative margins pose risks. Upside potential hinges on pipeline success and debt reduction, while competitive pressures and execution challenges remain key concerns for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Autonomous Technology & Robotics ETF
ARKQ is an actively managed ETF that invests in autonomous technology and robotics. It focuses on disruptive innovations like autonomous mobility, electric vehicles, 3D printing, and energy storage, with holdings such as Tesla and Teradyne.
Read more on ARKQ →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
